Bottom line
How much do IHE and XPH overlap?
17% of their top holdings overlap by weight. 12 securities appear in both funds' top 25, making up 18.0% of IHE's assets and 22.9% of XPH's. They are substantially different portfolios, so owning both adds real diversification.
Updated Nov 22, 2026
Overlap at a glance
Holdings IHE and XPH have in common
| Holding | % of IHE | % of XPH | Overlap |
|---|---|---|---|
| Merck & Co., Inc. | 4.55% | 1.65% | 1.65% |
| Elanco Animal Health Incorporated | 2.81% | 1.64% | 1.64% |
| Corcept Therapeutics Incorporated | 1.90% | 1.70% | 1.70% |
| Ligand Pharmaceuticals Incorporated | 1.45% | 1.94% | 1.45% |
| Definium Therapeutics Inc | 1.39% | 3.09% | 1.39% |
| Liquidia Corp | 1.28% | 1.86% | 1.28% |
| Indivior Pharmaceuticals, Inc. | 1.14% | 1.64% | 1.14% |
| Crinetics Pharmaceuticals Inc | 0.90% | 1.66% | 0.90% |
| Edgewise Therapeutics Inc | 0.70% | 1.88% | 0.70% |
| Amneal Pharmaceuticals, Inc. | 0.68% | 1.72% | 0.68% |
| Enliven Therapeutics Inc | 0.63% | 2.09% | 0.63% |
| Veradermics Inc | 0.56% | 2.02% | 0.56% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in IHE
- Johnson & Johnson — 22.44%
- Eli Lilly And Company — 22.25%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 6.24%
- Bristol-myers Squibb Company — 4.37%
- Royalty Pharma Plc — 4.34%
- Viatris Inc. — 4.22%
- Pfizer Inc. — 3.96%
- Zoetis Inc. — 3.73%
- Jazz Pharmaceuticals Public Limited Company — 3.45%
- Axsome Therapeutics, Inc. — 2.42%
- Organon & Co. — 0.81%
- Supernus Pharmaceuticals, Inc. — 0.62%
- Tarsus Pharmaceuticals Inc — 0.57%
Only in XPH
- State Street Global Advisors — 8.58%
- MBX Biosciences Inc — 2.72%
- Alumis Inc — 2.14%
- AtaiBeckley Inc — 2.13%
- Trevi Therapeutics Inc — 2.12%
- Amylyx Pharmaceuticals Inc — 2.04%
- Nuvation Bio Inc — 1.89%
- Nektar Therapeutics — 1.88%
- Maze Therapeutics Inc — 1.85%
- Harrow Inc — 1.81%
- EyePoint Inc — 1.77%
- Ocular Therapeutix Inc — 1.71%
- Pacira BioSciences Inc — 1.65%
Asset mix
| Asset type | IHE | XPH |
|---|---|---|
| Stocks | 99.9% | 100.0% |
| Cash & short-term funds | 6.3% | 8.6% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Country mix
| Country | IHE | XPH |
|---|---|---|
| US | 96.4% | 98.4% |
| GB | 4.3% | 1.6% |
| IE | 3.8% | 3.0% |
| CA | 1.4% | 3.1% |
| SG | 0.2% | 1.6% |
| KY | 0.2% | 1.0% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Check another pair
FAQ
How much do IHE and XPH overlap?
What stocks do IHE and XPH have in common?
Should I own both IHE and XPH?
Which holds more stocks, IHE or XPH?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.